Marshall Wace
NRIX icon

Marshall Wace’s Nurix Therapeutics NRIX Stock Holding History

Marshall Wace’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-246,788
Closed -$2.28M – 3312
2025
Q3 		$2.28M Buy
+246,788
New +$2.56M ﹤0.01% 1550
2023
Q4 		– Sell
-127,509
Closed -$1M – 2475
2023
Q3 		$1M Buy
+127,509
New +$1.16M ﹤0.01% 1503
2023
Q2 		– Sell
-21,497
Closed -$191K – 2810
2023
Q1 		$191K Buy
+21,497
New +$224K ﹤0.01% 2415
2022
Q1 		– Sell
-9,202
Closed -$267K – 3798
2021
Q4 		$267K Buy
+9,202
New +$279K ﹤0.01% 3068

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Marshall Wace's NRIX Position: Q4 2025 in Review

Marshall Wace sold out of Nurix Therapeutics (NRIX) in Q4 2025, closing a stake of 246,788 shares — an estimated $2.28M sold.

Marshall Wace first reported a position in NRIX in Q4 2021 and held it in 4 quarters. The position peaked at $2.28M in Q3 2025. 182 funds tracked by Wall St. Rank hold NRIX as of Q4 2025.

  • Marshall Wace reported no remaining Nurix Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Marshall Wace sold 246,788 Nurix Therapeutics shares in Q4 2025, an estimated $2.28M.
  • Marshall Wace first reported a position in Nurix Therapeutics in Q4 2021 and held it in 4 quarters.
  • Marshall Wace's Nurix Therapeutics position peaked at $2.28M in Q3 2025.
  • 182 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q4 2025.

Based on Marshall Wace's 13F filing for Q4 2025, filed 13 Feb 2026.